Pacira BioSciences Inc PCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Viatris Reports Third-Quarter 2026 Financial Results
Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders?
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
Trading Information
- Previous Close Price
- $36.42
- Day Range
- $36.42–36.45
- 52-Week Range
- $18.80–36.67
- Bid/Ask
- $36.26 / $36.44
- Shares Outstanding
- 39.91M
- Market Cap
- $1.45B
- Volume/Avg
- 537,093 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 14.01
- Price/Sales
- 2.02
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 6.76%
Company Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 829
- Website
- https://www.pacira.com
Valuation
Metric | PCRX |
|---|---|
Price/Earnings (Normalized) | 14.01 |
Price/Book Value | 2.04 |
Price/Sales | 2.02 |
Price/Cash Flow | 10.33 |
Price/Earnings
PCRX
Financial Strength
Metric | PCRX |
|---|---|
Quick Ratio | 3.32 |
Current Ratio | 4.68 |
Interest Coverage | 3.35 |
Quick Ratio
PCRX
Profitability
Metric | PCRX |
|---|---|
Return on Assets (Normalized) | 6.23% |
Return on Equity (Normalized) | 11.20% |
Return on Invested Capital (Normalized) | 7.32% |
Return on Assets
PCRX
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|$%%%&y< | LOCK|??%&r | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|MThB^nV$ | LOCK|Tq%Z> | $48B | |||
| Haleon PLC ADR HLN | LOCK|<RK%^b | LOCK|tm | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|JqYRq>@Z | LOCK|d>? | $32B | |||
| Viatris Inc VTRS | LOCK|%h>nMl | LOCK|M<q | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|!< | LOCK|$F | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|jY^#?& | LOCK|g@V | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|!<<YddV | LOCK|q< | $6B | |||
| Perrigo Co PLC PRGO | LOCK|R$S&Lr | LOCK|xp^ | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|lShF!< | LOCK|!kDQ> | $2B |
United States